Skip to main content
Premium Trial:

Request an Annual Quote

Aquila-Histoplex Named ACD's First European RNAscope Certified Service Provider

NEW YORK (GenomeWeb) – Advanced Cell Dx today announced Edinburgh, Scotland-based CRO Aquila-Histoplex as the first accredited RNAscope Certified Service Provider in Europe.

Aquila-Histoplex, which specializes in histological and multiplex staining technologies, has more than two years of experience performing the RNAscope assay for the academic and commercial research sectors, the company said in a statement.

Mike Millar, CEO of Aquila-Histoplex, said in a statement that the certification would ensure that the company can provide its clients with the highest quality RNA in situ hybridization data and is "a perfect tool for completing our portfolio."

ACD's RNAscope technology is an automated multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in formalin-fixed, paraffin-embedded tissues. It offers quantitative molecular detection along with morphological context in a single assay, the company said.

ACD, based in Hayward, Calif., develops cell and tissue-based analysis tools for personalized medicine.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.